Log in

NYSE:DGXQuest Diagnostics Stock Price, Forecast & News

$116.04
+1.99 (+1.74 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$114.40
Now: $116.04
$116.86
50-Day Range
$104.55
MA: $113.00
$122.61
52-Week Range
$73.02
Now: $116.04
$125.00
Volume854,185 shs
Average Volume1.40 million shs
Market Capitalization$15.52 billion
P/E Ratio19.97
Dividend Yield1.93%
Beta1.38
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic testing information and services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, Athena Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also offers risk assessment services for the life insurance industry; and health information technology solutions for healthcare organizations and clinicians. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.
Read More
Quest Diagnostics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.2Community Rank: 1.7Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.02 out of 5 stars


Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryHealth Care Services
SectorMedical
CUSIP74834L10
Phone973-520-2700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.73 billion
Cash Flow$9.09 per share
Book Value$42.22 per share

Profitability

Net Income$858 million

Miscellaneous

Employees47,000
Market Cap$15.52 billion
Next Earnings Date7/28/2020 (Estimated)
OptionableOptionable

Receive DGX News and Ratings via Email

Sign-up to receive the latest news and ratings for DGX and its competitors with MarketBeat's FREE daily newsletter.

Quest Diagnostics (NYSE:DGX) Frequently Asked Questions

How has Quest Diagnostics' stock been impacted by COVID-19 (Coronavirus)?

Quest Diagnostics' stock was trading at $99.73 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, DGX stock has increased by 16.4% and is now trading at $116.04. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Quest Diagnostics?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quest Diagnostics in the last year. There are currently 1 sell rating, 10 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Quest Diagnostics.

When is Quest Diagnostics' next earnings date?

Quest Diagnostics is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for Quest Diagnostics.

How were Quest Diagnostics' earnings last quarter?

Quest Diagnostics Inc (NYSE:DGX) announced its quarterly earnings data on Wednesday, April, 22nd. The medical research company reported $0.94 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.88 by $0.06. The medical research company had revenue of $1.82 billion for the quarter, compared to analysts' expectations of $1.76 billion. Quest Diagnostics had a return on equity of 14.79% and a net margin of 10.36%. The firm's revenue for the quarter was down 3.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.40 earnings per share. View Quest Diagnostics' earnings history.

How often does Quest Diagnostics pay dividends? What is the dividend yield for Quest Diagnostics?

Quest Diagnostics declared a quarterly dividend on Monday, May 18th. Shareholders of record on Wednesday, July 8th will be given a dividend of $0.56 per share on Wednesday, July 22nd. This represents a $2.24 annualized dividend and a yield of 1.93%. The ex-dividend date of this dividend is Tuesday, July 7th. View Quest Diagnostics' dividend history.

What price target have analysts set for DGX?

18 brokerages have issued 12 month price targets for Quest Diagnostics' shares. Their forecasts range from $85.00 to $146.00. On average, they expect Quest Diagnostics' share price to reach $114.78 in the next twelve months. This suggests that the stock has a possible downside of 1.1%. View analysts' price targets for Quest Diagnostics.

What are Wall Street analysts saying about Quest Diagnostics stock?

Here are some recent quotes from research analysts about Quest Diagnostics stock:
  • 1. According to Zacks Investment Research, "Quest Diagnostics reported a strong fourth quarter with both earnings and revenues beating the respective Zacks Consensus Estimate. Revenues for Diagnostic Information Services grew on strong volume growth, an easy comparable and acquisitions amid significant reimbursement pressure related to PAMA. We are upbeat about the company’s expanded network access, which helped accelerate volume growth in the quarter. The current-year outlook seems promising despite the company’s having reckoned another year of meaningful reimbursement. Quest Diagnostics has outperformed its industry over the past six months. On the flip side, the company is currently facing several PAMA-related reimbursement issues and pricing pressure. This apart, escalating costs and a tough competitive landscape are concerns." (3/16/2020)
  • 2. Evercore ISI analysts commented, "We spent time on the west coast last week (LA + SF weather right now >>> Diagnostics (CFO and IR). Post solid 1H results after a reset in sentiment, numbers, and multiples last year, it is safe to say investor perception has recovered somewhat and the focus has shifted back towards the longer term path with the possibility of regulatory easing (particularly as organic volumes surprised last Q)." (8/8/2019)

Has Quest Diagnostics been receiving favorable news coverage?

Media stories about DGX stock have been trending negative recently, InfoTrie reports. The research firm ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Quest Diagnostics earned a media sentiment score of -2.2 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 5.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the next few days. View the latest news about Quest Diagnostics.

Are investors shorting Quest Diagnostics?

Quest Diagnostics saw a decline in short interest in June. As of June 30th, there was short interest totaling 3,290,000 shares, a decline of 16.1% from the June 15th total of 3,920,000 shares. Based on an average trading volume of 1,890,000 shares, the short-interest ratio is currently 1.7 days. Currently, 2.5% of the shares of the stock are sold short. View Quest Diagnostics' Current Options Chain.

Who are some of Quest Diagnostics' key competitors?

What other stocks do shareholders of Quest Diagnostics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Quest Diagnostics investors own include CA (CA), BlackRock (BLK), Johnson & Johnson (JNJ), Endologix (ELGX), Micron Technology (MU), Gilead Sciences (GILD), Chipotle Mexican Grill (CMG), Procter & Gamble (PG), Cisco Systems (CSCO) and QUALCOMM (QCOM).

Who are Quest Diagnostics' key executives?

Quest Diagnostics' management team includes the following people:
  • Mr. Stephen H. Rusckowski, Chairman, Pres & CEO (Age 62)
  • Mr. Mark J. Guinan, Exec. VP & CFO (Age 57)
  • Ms. Catherine T. Doherty, Sr. VP and Group Exec. of Clinical Franchise Solutions & Marketing (Age 56)
  • Mr. James E. Davis, Exec. VP of Gen. Diagnostics (Age 56)
  • Ms. Carrie Eglinton Manner, Sr. VP of Advanced Diagnostics (Age 44)

What is Quest Diagnostics' stock symbol?

Quest Diagnostics trades on the New York Stock Exchange (NYSE) under the ticker symbol "DGX."

Who are Quest Diagnostics' major shareholders?

Quest Diagnostics' stock is owned by a variety of retail and institutional investors. Top institutional investors include First Financial Bank Trust Division (0.06%), Nelson Van Denburg & Campbell Wealth Management Group LLC (0.00%) and Thomasville National Bank (0.00%). Company insiders that own Quest Diagnostics stock include Catherine T Doherty, Everett Cunningham, Gail R Wilensky, J E Davis, Manner Carrie Eglinton, Mark Guinan, Michael E Prevoznik, Michael J Deppe and Stephen H Rusckowski. View institutional ownership trends for Quest Diagnostics.

Which institutional investors are selling Quest Diagnostics stock?

DGX stock was sold by a variety of institutional investors in the last quarter, including Thomasville National Bank. Company insiders that have sold Quest Diagnostics company stock in the last year include Catherine T Doherty, Gail R Wilensky, J E Davis, Manner Carrie Eglinton, Michael E Prevoznik, Michael J Deppe, and Stephen H Rusckowski. View insider buying and selling activity for Quest Diagnostics.

Which institutional investors are buying Quest Diagnostics stock?

DGX stock was purchased by a variety of institutional investors in the last quarter, including First Financial Bank Trust Division, and Nelson Van Denburg & Campbell Wealth Management Group LLC. View insider buying and selling activity for Quest Diagnostics.

How do I buy shares of Quest Diagnostics?

Shares of DGX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Quest Diagnostics' stock price today?

One share of DGX stock can currently be purchased for approximately $116.04.

How big of a company is Quest Diagnostics?

Quest Diagnostics has a market capitalization of $15.52 billion and generates $7.73 billion in revenue each year. The medical research company earns $858 million in net income (profit) each year or $6.56 on an earnings per share basis. Quest Diagnostics employs 47,000 workers across the globe.

What is Quest Diagnostics' official website?

The official website for Quest Diagnostics is www.questdiagnostics.com.

How can I contact Quest Diagnostics?

Quest Diagnostics' mailing address is 500 PLAZA DRIVE, SECAUCUS NJ, 07940. The medical research company can be reached via phone at 973-520-2700 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.